Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy
Developing Artificial Intelligence-based Algorism Based on Life-log Data Acquired From Wearable Device for the Prediction of Chemotherapy-induced Side Effects and Symptom
Sehhoon Park
500 participants
Jun 8, 2023
OBSERVATIONAL
Conditions
Summary
In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate chemotherapy completion rates, emergency room visits, and frequency of CTCAE adverse events. The investigators will develop an artificial intelligence-based algorism that can predict patients' side effects based on biomarkers alone.
Eligibility
Inclusion Criteria7
- years of age or older
- Must have diagnosed with lung, head and neck, or esophageal cancer,
- scheduled to receive their first treatment in preoperative or postoperative chemotherapy.
- scheduled for systemic chemotherapy due to recurrence or metastasis.
- Eastern Cooperative Oncology (ECOG) performance status of 0 to 2.
- Patients who have access to a smartphone and can use the mobile app on their own.
- Understand the purpose of the study and agree to participate in the study.
Exclusion Criteria2
- Patients who, in the judgment of the researcher, have difficulty using the application.
- Patients who are judged by the medical staff to be unable to participate in the study.
Interventions
Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05937477